Market Overview

UPDATE: Jefferies Initiates AbbVie at Buy on Growth Outlook, High Yield

Share:
Related ABBV
AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage Triple-Negative Breast Cancer
Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting
Gilead's (GILD) HCV Drug Harvoni Gets Approval in Japan - Analyst Blog (Zacks)

Jefferies initiated coverage on AbbVie (NYSE: ABBV) with a Buy rating and a $44.00 price target.

Jefferies commented, "AbbVie is our top pick for 2013. We see the initial trading volatility post-spin as an opportune entry point into the shares as we soon expect income funds to work the dividend yield down to at least the 4.0% level. A more durable long-term performance from Humira, stronger pipeline delivery and operating margin expansion drive our cash EPS estimates up to 22% ahead of consensus."

AbbVie closed at $34.09 on Tuesday.

Latest Ratings for ABBV

DateFirmActionFromTo
Jun 2015Piper JaffrayInitiates Coverage onOverweight
Jun 2015JefferiesMaintainsBuy
May 2015Morgan StanleyAssumesEqual-weight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Get Benzinga's Newsletters